Yourgene have worked closely with Key Opinion Leaders, high profile partners, customers and market renowned experts within their chosen fields to develop a series of Your Expert papers. We aim to cover a range of different topics and content relevant to the portfolio of applications that Yourgene operates in. We aspire that these papers are relevant, informative, educational and add value. Enjoy.
Roll your mouse over the item to view.
Achieving cost savings in NIPT by enabling greater flexibility in blood collection tube choice
Non-invasive prenatal testing (NIPT) involves sequencing cell-free DNA (cfDNA) from maternal plasma to screen for fetal trisomy 21, 18, and 13, and in some instances other chromosomal abnormalities. Making NIPT routinely available has required the use of blood collection tubes (BCTs)that maintain the sample at ambient temperatures, whilst also retaining the integrity of the cell-free DNA (cfDNA) population.
DOWNLOAD PAPER
Collaboration to Perform: Yourgene Health and LifeStrands Genomics
Yourgene Health spoke with Dr Keith Byron, Chief Operating Officer at LifeStrands Genomics, a market leader of accredited clinical laboratory services and solutions in southeast Asia, including non-invasive prenatal testing (NIPT).
DOWNLOAD PAPER
Size Selection of Cell-free DNA Increases the Proportion of Tumor Specific Variants in Cancer Patients.
To view the full webinar, by Kim Holden from Labcorp, discussing ‘Getting to the DNA you care about in Liquid Biopsy’, using our LightBench®, Powered by Ranger® Technology - click the link below.
VIEW THE WEBINAR
or
DOWNLOAD THE PAPER
The Truth About Statistics in NIPT
Non-invasive prenatal testing (NIPT) is a relatively new tool in prenatal care, helping clinicians to assess the chance of fetal chromosomal abnormalities early in a pregnancy. It is more accurate than traditional screening techniques for common fetal aneuploidies – Down’s syndrome, Patau’s syndrome, and Edwards’ syndrome – and carries no
associated miscarriage risk.
DOWNLOAD PAPER
A true Manchester partnership advancing precision medicine
Yourgene spoke with Joely Irlam-Jones, a Research Associate at the University of Manchester and Director and CEO of ManTRa Diagnostics, a spin-out company from the University of Manchester that is developing patient stratification solutions to personalise medicine and improve cancer treatment outcomes. The team have developed tumour-site-specific gene expression signatures which indicate the oxygen status of the tumour. ManTRa and the Yourgene Genomic Services team have a longstanding history of over 10 years working together on this development.
DOWNLOAD PAPER
NIPT screening: Ticking all the boxes
Future Health is the UK’s largest Stem Cell Bank with over 20 years of history and experience. They have 2 storage facilities, one in the UK and one in Switzerland and a physical presence in over 40 countries worldwide. Future Health do not just offer stem cell banking, their services include screening, both NIPT and newborn screening.
DOWNLOAD PAPER
A private Provider's view on NIPT
Non-invasive prenatal screening (NIPT) is available in the form of the IONA® test and IONA® Care from Yourgene Health’s Genomic Services laboratory in Manchester, UK. The test requires a maternal blood sample from the 10th week of gestation and uses next generation sequencing to determine the likelihood that the pregnancy is affected by trisomy 21, 18 or 13.
DOWNLOAD PAPER
Alzheimer’s disease and polygenic risk score
Yourgene’s Director of Marketing, Jo Cross, interviewed Dr Richard Pither, CEO of Cytox about genoSCORE™-LAB – a polygenic risk score test for understanding a patient’s risk of developing Alzheimer’s disease. Yourgene Genomic Services run the genoSCORE™-LAB test in their Manchester laboratory.
DOWNLOAD PAPER
LightBench®: Enabling liquid biopsies for cancer detection
A Yourgene Health LightBench® customer, Dr Hunter Underhill is an Assistant Professor of Paediatrics within the medical genetics’ division at the University of Utah School of Medicine. He has a research lab at the Huntsman Cancer Institute studying the applicability of cfDNA detection for brain tumour surveillance and monitoring.
DOWNLOAD PAPER
Patient and healthcare provider views on DPD deficiency screening
Fluorouracil (5-FU) and Capecitabine, a prodrug of 5-FU, are fluoropyrimidine chemotherapy agents used in the treatment of cancer. These drugs form a key component of the chemotherapy regime for colorectal, breast, heapato-pancreato-biliary and many other cancers..
DOWNLOAD PAPER
The Clinical Applications of Next Generation Sequencing the sharing of a Case Experience
Through high throughput techniques, NGS technology is able to thoroughly screen and record human gene sequences, supporting the performing of clinical researches and medical diagnoses. Preventive genetic testing can be employed to analyze the risks and risk degrees of the hereditary disease-associated genes for general examinees. Furthermore, diagnosed patients can be tested to provide physicians with background information for the planning of target therapy strategies or the assessing and monitoring of disease recurrences.
DOWNLOAD PAPER
Achieving cost savings in NIPT by enabling greater flexibility in blood collection tube choice
The development of prenatal molecular testing has progressed from the early large segment chromosomal abnormality observation method, to DNA microarray technology, then into whole genome sequencing (WGS) and whole exome sequencing (WES), with every stage having its own advantages and disadvantages.
